Health Economics›Hepatocellular carcinoma›First-line therapy for advanced or metastatic disease

First-line therapy for advanced or metastatic disease

Hepatocellular carcinoma · 26 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Durvalumab and Tremelimumab Variant #01 Partial	—	R 131 701	28d	—	16.4 mo	—	—	3
Lenvatinib monotherapy Variant #01	—	R 74 494	28d	8.0 mo	16.0 mo	9	R 670 444 PFS proxy	5
Durvalumab monotherapy Variant #01	—	R 61 460	14d	—	16.6 mo	—	—	2
Atezolizumab and Bevacizumab Variant #01	—	R 59 878	21d	—	19.2 mo	—	—	1
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	~4.9 mo	—	~8	~R 457 971 PFS proxy · indirect	—
Erlotinib and Bevacizumab Variant #01	—	R 52 071	28d	~16.4 mo	~49.1 mo	~18	~R 937 282 PFS proxy · indirect	7
Sorafenib monotherapy Variant #04	—	R 37 339	28d	3.7 mo	10.7 mo	5	R 186 694 PFS proxy	33
Sunitinib monotherapy Variant #05	—	R 33 433	28d	—	7.9 mo	—	—	1
Capecitabine and Bevacizumab Variant #01	—	R 29 610	21d	~9.1 mo	—	~14	~R 414 534 PFS proxy · indirect	7
CapeOx and Bevacizumab Variant #01	—	R 16 696	21d	~10.3 mo	—	~15	~R 250 437 PFS proxy · indirect	4
Doxorubicin and Sorafenib Variant #01	—	R 16 577	21d	—	13.7 mo	—	—	1
GemOx and Sorafenib Variant #01	—	R 13 165	14d	—	—	—	—	—
mFOLFOX and Sorafenib Variant #01	—	R 12 391	14d	—	—	—	—	—
CapeOx Variant #01	—	R 2 384	21d	~6.7 mo	~12.2 mo	~10	~R 23 842 PFS proxy · indirect	20
GemOx Variant #01	—	R 2 335	14d	~5.0 mo	~9.0 mo	~11	~R 25 688 PFS proxy · indirect	5
Capecitabine monotherapy Variant #17	—	R 2 219	21d	~5.7 mo	~7.5 mo	~9	~R 19 974 PFS proxy · indirect	11
FOLFOX4 Variant #01	—	R 2 064	14d	—	6.4 mo	—	—	1
FULV Variant #01	—	R 1 466	35d	~5.6 mo	~13.1 mo	~5	~R 7 330 PFS proxy · indirect	15
Doxorubicin monotherapy Variant #10	—	R 1 293	21d	—	6.5 mo	—	—	4
Tamoxifen monotherapy Variant #06	—	R 410	28d	—	6.0 mo	—	—	—
Nivolumab monotherapy Variant #01 Partial	—	—	14d	—	16.4 mo	—	—	1
Placebo Partial	—	—	—	—	4.2 mo	—	—	3
Best supportive care Partial	—	—	—	—	16.0 mo	—	—	3
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	16.0 mo	—	—	1
Apatinib and Camrelizumab Variant #01 Partial	—	—	14d	5.6 mo	23.0 mo	13	—	4
Donafenib monotherapy Variant #01 Partial	—	—	28d	—	12.1 mo	—	—	1

26 of 26 regimens shown